Navigation Links
Bionovo to Present Recent Findings of BN107 and BN108, Its Anticancer Agents, at the American Association of Cancer Research
Date:4/15/2008

EMERYVILLE, Calif., April 15 /PRNewswire-FirstCall/ -- Bionovo Inc. (Nasdaq: BNVI) will present findings on the mechanism of action of two of its anti-cancer agents BN107 and BN108 at the American Association of Cancer Research (AACR) being held at the San Diego Convention Center in San Diego, CA, April 12 - 16, 2008.

Bionovo's poster presentation will describe the pathway for cancer cell apoptosis (cell death) induced by BN107 and BN108. As explained by Dr. Emma Shtivelman, Director of Cancer Research at Bionovo, the ability of BN107 to induce death cancer cell death is distinct from that of BN108. BN107 induces apoptosis through the mitochondrial pathway. BN107 induces death only in estrogen receptor negative breast cancer cells. BN108 induces cancer cell death by rapid inactivation of both AKT and mTOR pathways in breast cancer cells, but not in normal cells.

"BN107 and BN108 mechanisms of action and unique selective properties are a result of some of the biological differences between cancer cells and normal cells as well as cancer cells' uniquely acquired functions," said Dr. Isaac Cohen, President and CEO of Bionovo. "We believe both drugs will result in better tolerability and better toxicity profile than conventional chemotherapy due to better target selectivity. Oral administration will provide availability for chronic treatment and will mark these new targeted compounds as promising investigational drugs."

Bionovo, Inc.

Bionovo is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and
'/>"/>

SOURCE Bionovo Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Bionovo Identifies and Describes ER-beta Selective Compounds for the Treatment of Vaginal Dryness
2. Louis Drapeau Joins Bionovos Board of Directors
3. George Butler Joins Bionovos Board of Directors
4. Bionovo to Present at Bank of Montreals 2007 Focus on Healthcare Conference
5. Bionovo Announces Third Quarter 2007 Financial Results
6. Bionovo Announces the Pricing of Public Offering of Shares of Common Stock
7. Bionovo to Present at the Biotechnology Industry Organization (BIO) Investor Forum
8. Bionovo Announces Proposed Public Offering of Common Stock
9. Bionovo to Present at A.G. Edwards 2nd Annual Emerging Growth Conference 2007
10. ARIUS presents new findings for anti-cancer antibody programs at AACR
11. Monogram Biosciences to Present at the JMP Securities Seventh Annual Research Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... Atlanta, GA (PRWEB) May 17, 2013 ... Obstetrics, Gynecology, and Women’s Health at the Albert Einstein ... of Oncology at the Montefiore Medical Center. He ... Einstein Cancer Center and leads the Einstein Breast Cancer ... focused on translational breast cancer research. He also serves ...
(Date:5/17/2013)... transplant recipient,s immune system identifies the transplanted organ as ... that T cells, the immune cells that mediate rejection, ... in order to migrate to the transplanted organ. In ... , Fadi Lakkis and colleagues at the University of ... T cells is not required for migration. Instead, these ...
(Date:5/17/2013)... world-leading provider of scientific, technical and medical information products ... study in Reproductive BioMedicine Online ... an abnormal chromosomal composition can be identified by the ... classifying the risk of genetic abnormality without a biopsy. ... a retrospective study, using their predictive model to assess ...
(Date:5/17/2013)... 17, 2013 •    First of its kind ... sustainability ,     New facility will help solve crop ... Syngenta unveiled its new crop research facility ... RTP Innovation Center. The first of its kind, $72 ... any agricultural climate and precisely measure plant inputs – ...
Breaking Biology Technology:Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group 2Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group 3Breakthrough for IVF? 2Breakthrough for IVF? 3Syngenta Opens Unique $72 Million Advanced Crop Lab 2Syngenta Opens Unique $72 Million Advanced Crop Lab 3
... & Conference Held in Pittsburgh - Over 1,000 Expected ... Attendees to Discuss New Technologies, New Business, PITTSBURGH, ... forum for the growing business of using,waste materials and ... will take place in downtown Pittsburgh,s David L. Lawrence,Convention ...
... Speaker at AdvaMed 2008 - Book signing to ... Healthcare policy,regulatory environment, elements of the global marketplace, ... 2008 MedTech Conference., Wednesday panel presentations will ... the wireless & IT sectors, remote patient monitoring,technologies, ...
... Researchers at The University of Texas at San Antonio (UTSA) ... of Texas Health Science Center at San Antonio (UTHSCSA) have ... controlling the early infectious process against Francisella tularensis, ... of tularemia. The findings will be released this week in ...
Cached Biology Technology:Former Speaker of the House Newt Gingrich Featured Wednesday 2UTSA/UTHSCSA publish results on bio-threat agent 2
(Date:5/16/2013)... (GWA), where the entirety of an individual,s DNA is ... which can cause health problems is a massively useful ... pose major ethical problems if used incorrectly, say new ... published on line today (16 May 2013) in the ... based on whole genome and on exome* sequencing and ...
(Date:5/16/2013)... 2013 Reportlinker.com announces that a ... its catalogue: Global Biometric ... http://www.reportlinker.com/p01181929/Global-Biometric-Systems-Market-Forecast--Opportunities-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Security_Systems Lack ... such as photographs, passwords and PIN codes ... in last few years. Security threats such ...
(Date:5/15/2013)... trial to date to examine the efficacy of PARP ... than breast and ovarian cancer, the oral drug olaparib ... prostate cancers. Results of the study, led by researchers ... of Pennsylvania and Sheba Medical Center in Tel Hashomer, ... Clinical Oncology,s annual meeting in Chicago in early June ...
Breaking Biology News(10 mins):European Society of Human Genetics urges caution over use of new genetic sequencing techniques 2Global Biometric Systems Market Forecast & Opportunities, 2018 2Global Biometric Systems Market Forecast & Opportunities, 2018 3Global Biometric Systems Market Forecast & Opportunities, 2018 4Global Biometric Systems Market Forecast & Opportunities, 2018 5Global Biometric Systems Market Forecast & Opportunities, 2018 6Global Biometric Systems Market Forecast & Opportunities, 2018 7PARP inhibitor shows activity in pancreatic, prostate cancers among patients carrying BRCA mutations 2
... was originally believed to be involved in tuberculosis antibiotic ... pathway for an agent used by the bacteria to ... of the Week" in the April 8 issue of ... Biochemistry and Molecular Biology journal. , Mycobacterium tuberculosis, the ...
... be brought to the marketplace, giving laboratories everywhere ... Transfer GmbH (EMBLEM), the commercial entity of the ... it has signed a licensing deal with technological ... called SPIM (Selective Plane Illumination Microscopy). , "Microscopes ...
... very special mice, scientists have discovered a new tumor ... the development of human leukemia, findings that open up ... say. , Researchers in The Ohio State University Comprehensive ... acute lymphoblastic leukemia (ALL). The mouse first goes through ...
Cached Biology News:Scientists find missing enzyme for tuberculosis iron scavenging pathway 2The transparent organism: EMBLEM and Carl Zeiss give labs a unique look at life 2Genome-wide mouse study yields link to human leukemia 2Genome-wide mouse study yields link to human leukemia 3
Goat polyclonal to NIR1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: SWARGPPKFESVP, corresponding to C terminal amino acids 962-974 of NIR1. Entrez Gene ID: 83394 ...
HOXC11 Antibody...
Anti-MMP-14, catalytic domain, clone LEM-2/15.8 Immunogen: Synthetic peptide: amino acid sequence 218-233 within the catalytic domain Available Date: 38579...
Anti-MMP-19 (RASI), carboxy terminal region; rabbit host...
Biology Products: